To rapidly analyze the active components of the Qufeng Xiaodian Formula(QFXDF)，as well as to explore and verify its mechanism in treating Henoch Schnlein purpura(HSP) through network pharmacology.Methods:Ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry(UPLC-Q-TOF/MSE) technology was combined with UNIFI analysis software to quickly and qualitatively analyze the components in QFXDF.Swiss Target Prediction，OMIM，PharmGkb，and other databases were employed to screen the targets of QFXDF components and HSP，constructing the “component-target-disease” network and protein-protein interaction(PPI) network.Then，Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis were performed.The molecular docking method was used to analyze the binding effect of the main active components in QFXDF and core targets.Finally，Western blot and immunohistochemistry were utilized to further detect the effects of QFXDF on key pathways and key targets in HSP model rats.Results:There were 41 identified components from QFXDF，which shared 149 potential targets co-acted with HSP diseases，including epidermal growth factor receptor(EGFR)，caspase 3(CASP3)，interleukin 2(IL-2)，and others.The main signaling pathways related to KEGG enrichment included PI3K/AKT signaling pathway，Th17 cell differentiation，VEGF signaling pathway，and so on.The active components of QFXDF had relatively strong binding ability with key target proteins.Animal experimental results proved that QFXDF could significantly improve the pathological damage of skin and kidney in HSP rat models，inhibit the high expression of EGFR and CASP3 in skin and kidney tissues，and inhibit the PI3K/AKT signaling pathway activation.Conclusion:It is preliminarily confirmed that QFXDF can treat HSP by regulating targets such as EGFR and CASP3，as well as the PI3K/AKT signaling pathway，which provides a basis for further elucidation of the mechanism and clinical application of QFXDF